Lars Hvass

Mr. Lars Hvass

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 February 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
RGRocío García-Vázquez
Rocío García-Vázquez
JJJesper Tranekjær Jørgensen
Jesper Tranekjær Jørgensen
KBKlas Bratteby
Klas Bratteby
VSVladimir Shalgunov
Vladimir Shalgunov
LHLars Hvass
Lars Hvass
UBUmberto Maria Battisti
Umberto Maria Battisti
Pretargeted PET imaging is an emerging and fast-developing method to monitor immuno-oncology strategies. Currently, tetrazine ligation is considered the most promising bioorthogonal reaction for pretargeting in vivo. Recently, we have developed a method to 18F-label ultrareactive tetrazines by copper-mediated fluorinations. However, bispyridyl tetrazines—one of the most promising structures for in vivo pretargeted applications—were inaccessible using this strategy. We believed that our successful efforts to 18F-label H-tetrazines using low basic labeling conditions could also be used to label bispyridyl tetrazines via aliphatic nucleophilic substitution. Here, we report the first direct 18F-labeling of bispyridyl tetrazines, their optimization for in vivo use, as well as their successful application in pretargeted PET imaging. This strategy resulted in the design of [18F]45, which could be labeled in a satisfactorily radiochemical yield (RCY = 16%), molar activity (Am = 57 GBq/µmol), and high radiochemical purity (RCP > 98%). The [18F]45 displayed a target-to-background ratio comparable to previously successfully applied tracers for pretargeted imaging. This study showed that bispyridyl tetrazines can be developed into pretargeted imaging agents. These structures allow an easy chemical modification of 18F-labeled tetrazines, paving the road toward highly functionalized pretargeting tools. Moreover, bispyridyl tetrazines led to near-instant drug release of iTCO-tetrazine-based ‘click-to-release’ reactions. Consequently, 18F-labeled bispyridyl tetrazines bear the possibility to quantify such release in vivo in the future.

18 February 2025 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MHMatthias M. Herth
Matthias M. Herth
LHLars Hvass
Lars Hvass
CPChristian Poulie
Christian Poulie
MMMarius Müller
Marius Müller
RGRocio García-Vázquez
Rocio García-Vázquez
UBUmberto Maria Battisti
Umberto Maria Battisti

6 November 2025 in Molecular Pharmaceutics
Verified
Journal Article
Open access
TGTobias Gustavsson
Tobias Gustavsson
TKThomas Kustermann
Thomas Kustermann
LHLars Hvass
Lars Hvass
TWThomas E. Wuensche
Thomas E. Wuensche
ACAnne Skovsbo Clausen
Anne Skovsbo Clausen
MHMatthias M. Herth
Matthias M. Herth
Pretargeted PET imaging offers a powerful approach to improve nuclear imaging contrast and reduce systemic radiation exposure, yet its application in the brain has been limited by the blood-brain barrier (BBB). Here, we demonstrate, for the first time, successful pretargeted PET imaging of a brain target enabled by a bispecific antibody engineered for transferrin receptor-mediated BBB transcytosis. By combining this brain shuttle with a novel 18F-labeled tetrazine, we achieve specific, quantifiable detection of brain-localized Aβ aggregates, validated through PET imaging and histological analysis. This proof-of-concept establishes a versatile, noninvasive imaging platform with broad potential for assessing biologic drug candidates and CNS targets previously considered intractable.

13 March 2025 in Molecular Pharmaceutics
Verified
Journal Article
Open access
LHLars Hvass
Lars Hvass
MMMarius Müller
Marius Müller
MSMarkus Staudt
Markus Staudt
RGRocio García-Vázquez
Rocio García-Vázquez
TGTobias K. Gustavsson
Tobias K. Gustavsson
Andreas KjaerAndreas Kjaer
Andreas Kjaer
Pretargeted imaging harnessing tetrazine ligation has gained increased interest over recent years. Targeting vectors with slow pharmacokinetics may be visualized using short-lived radionuclides, such as fluorine-18 (18F) for positron emission tomography (PET), and result in improved target-to-background ratios compared to conventionally radiolabeled slowly accumulating vectors. We recently developed different radiochemical protocols enabling the direct radiofluorination of various tetrazine scaffolds, resulting in the development of various highly reactive and polar 18F-labeled tetrazines as lead candidates for pretargeted imaging. Here, we performed a direct head-to-head-comparison of our lead candidates to evaluate the most promising for future clinical translation. For that, all 18F-labeled tetrazine-scaffolds were synthesized in similar molar activity for improved comparability of their in vivo pretargeting performance. Intriguingly, previously reported dicarboxylic acid lead candidates with a net charge of -1 were outperformed by respective monocarboxylic acid derivatives bearing a net charge of 0, warranting further evaluation of such scaffolds prior to their clinical translation.

18 February 2026 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
MZMerlin Zabrocki
Merlin Zabrocki
SDSamantha Delaney
Samantha Delaney
LHLars Hvass
Lars Hvass
UBUmberto Maria Battisti
Umberto Maria Battisti
Andreas KjaerAndreas Kjaer
Andreas Kjaer
MHMatthias M. Herth
Matthias M. Herth

13 September 2024 in Diagnostics
Verified
Journal Article
Open access
PDF file
JMJulie van Krimpen Mortensen
Julie van Krimpen Mortensen
SMSimona Mattiussi
Simona Mattiussi
LHLars Hvass
Lars Hvass
ELEmilie Graae Lund
Emilie Graae Lund
VSVladimir Shalgunov
Vladimir Shalgunov
Andreas KjaerAndreas Kjaer
Andreas Kjaer
The use of fibroblast activation protein inhibitors (FAPis) for positron emission tomography (PET) imaging in cancer has garnered significant interest in recent years, yielding promising results in preclinical and clinical settings. FAP is predominantly expressed in pathological conditions such as fibrosis and cancer, making it a compelling target. An optimized approach involves using FAPi homodimers as PET tracers, which enhance tumor uptake and retention, making them more effective candidates for therapy. Here, a UAMC-1110 inhibitor-based homodimer, DOTAGA-Glu(FAPi)2, was synthesized and radiolabeled with gallium-68, and its efficacy was evaluated in vivo for PET imaging in an endogenously FAP-expressing xenografted mouse model, U87MG. Notably, 45 min post-injection, the mean uptake of [68Ga]Ga-DOTAGA-Glu(FAPi)2 was 4.7 ± 0.5% ID/g in the tumor with low off-target accumulation. The ex vivo analysis of the FAP expression in the tumors confirmed the in vivo results. These findings highlight and confirm the tracer’s potential for diagnostic imaging of cancer and as a theranostic companion.